Coughlin, Gerard M. https://orcid.org/0000-0003-0644-4721
Borsos, Máté https://orcid.org/0000-0002-2801-8910
Barcelona, Bre’Anna H. https://orcid.org/0009-0007-1897-1461
Appling, Nathan https://orcid.org/0009-0007-9488-6621
Mayfield, Acacia M. H. https://orcid.org/0000-0001-7308-6480
Mackey, Elisha D.
Eser, Rana A. https://orcid.org/0000-0003-4078-1502
Jackson, Cameron R.
Chen, Xinhong https://orcid.org/0000-0003-0408-0813
Kumar, Sripriya Ravindra https://orcid.org/0000-0001-6033-7631
Gradinaru, Viviana https://orcid.org/0000-0001-5868-348X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (UF1MH128336)
Michael J. Fox Foundation for Parkinson's Research (ASAP-020495)
Chan Zuckerberg Initiative Neurodegeneration Challenge Network
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Article History
Received: 23 December 2023
Accepted: 17 January 2025
First Online: 20 March 2025
Competing interests
: V.G. is a co-founder and board member of Capsida Biotherapeutics, a fully integrated AAV engineering and gene therapy company. The remaining authors declare no competing interests.